Broad Institute

MARCH 22, 2024

Messenger RNAs with multiple “tails” could lead to more effective therapeutics By Corie Lok March 22, 2024 Breadcrumb Home Messenger RNAs with multiple “tails” could lead to more effective therapeutics Scientists have engineered long lasting mRNAs that increased therapeutic protein production in cells and animals.

Engineering 140

Engineering Protein Production RNA Vaccine 140

Broad Institute

MAY 14, 2024

William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. In 2020, scientists used the T7 platform to produce enough mRNA for COVID-19 vaccines to vaccinate millions of people in the U.S.

RNA 84

RNA Production Molecular Biology Laboratories 84

Drug Target Review

MARCH 15, 2024

Advancements in cell line development (CLD), including screening and selection of final clones, scale up, automation and digitalisation have enabled precision and enhanced productivity. Efforts have focused on Chinese hamster ovary (CHO) cell line improvements since it is a commonly used host for the expression of therapeutic proteins.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

Codon

MARCH 24, 2024

The market for semaglutide-based products is projected to swell to $71B in less than a decade. All of this future value, of course, relies upon these companies actually making enough of their product to meet the growing demand. In November, Novo Nordisk invested $6B in additional production capacity.

Engineering 85

Engineering Vaccine Production RNA 85

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. JS Bio’s parent company.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52

The Pharma Data

JANUARY 13, 2021

The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.

Licensing 52

Licensing Licensing Clinical Trials Trials 52

Codon

MAY 30, 2023

Biosynthesis of cannabigerol and cannabigerolic acid, the gateways to further cannabinoid production. Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. Synthetic Biology. coli cells. Nature Chemical Biology.

DNA 52

DNA RNA Engineering Vaccine 52